TABLE 2.
Survival analysis
| No. of patients | Univariate | Multivariate‐model1 | Multivariate‐model2 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P‐value | HR | 95% CI | P‐value | HR | 95% CI | P‐value | ||
| Factors at the start of the second line therapy | ||||||||||
| Age | ||||||||||
| ≥65 | 19 | 1.01 | (0.56–1.84) | 0.97 | ||||||
| <65 | 40 | 1 | ||||||||
| Sex | ||||||||||
| Male | 32 | 0.98 | (0.55–1.72) | 0.96 | ||||||
| Female | 27 | |||||||||
| BMI | ||||||||||
| <22 | 19 | 0.69 | (0.37–1.26) | 0.22 | ||||||
| ≤22 | 40 | 1 | ||||||||
| ECOG PS | ||||||||||
| ≥2 | 8 | 3.51 | (1.58–7.79) | 0.002* | 2.61 | (1.13–6.07) | 0.025* | 2.35 | (1.02–5.42) | 0.044* |
| <2 | 51 | 1 | 1 | 1 | ||||||
| Tumor location | ||||||||||
| Head | 24 | 1.18 | (0.67–2.08) | 0.58 | ||||||
| Body and Tail | 35 | 1 | ||||||||
| CAR | ||||||||||
| ≻0.16 | 25 | 3.25 | (1.80–5.89) | 0.0001* | 3.03 | (1.57–5.87) | 0.0009* | 3.47 | (1.76–6.84) | 0.0003* |
| ≤ 0.16 | 34 | 1 | 1 | 1 | ||||||
| NLR | ||||||||||
| ≻4 | 16 | 1.67 | (0.91–3.06) | 0.11 | ||||||
| ≤4 | 43 | 1 | ||||||||
| Ca19‐9 | ||||||||||
| >1000 ng/ml | 37 | 2.10 | (1.04–4.26) | 0.038* | 2.06 | (0.98–4.32) | 0.055 | 1.86 | (0.88–3.95) | 0.10 |
| ≤1000 ng/ml | 16 | 1 | 1 | 1 | ||||||
| Second line therapy | ||||||||||
| mFFX | 29 | 1.01 | (0.57–1.79) | 0.96 | ||||||
| S‐1 | 30 | 1 | ||||||||
| Decrease rate in body weight | ||||||||||
| ≥5% | 1.92 | (1.08–3.42) | 0.027* | 1.28 | (0.68–2.43) | 0.45 | ||||
| <5% | 1 | 1 | ||||||||
| Either Fat or SMI loss during the first line therapy | ||||||||||
| Present | 30 | 2.57 | (1.44–4.60) | 0.0014* | 2.29 | (1.20–4.37) | 0.010* | |||
| Absent | 29 | 1 | 1 | |||||||
Note: Fat loss means decrease in visceral fat area (>34.1%) or subcutaneous fat area (>8.5%). Multivariate analysis was conducted between factors with P‐value <0.10 in univariate analysis.
Abbreviations: BMI, body mass index; CAR, CRP–albumin ratio; NLR, neutrophil–lymphocyte ratio, SMI, skeletal muscle index.